InvestorsHub Logo
Followers 44
Posts 5637
Boards Moderated 0
Alias Born 10/28/2009

Re: Lestatk post# 70

Wednesday, 05/20/2015 3:37:24 PM

Wednesday, May 20, 2015 3:37:24 PM

Post# of 158
Be conscious that this is a very young medical research company. Short term it is encouraging they have moved from a penny to a larger exchange. The CEO was explicit in the first investor call. The company is up front that cancer detection blood test kits will not roll out until mid-2016 at the earliest and later for the US market because of FDA scrutiny. More investors will research and post hear after the pancreas and other larger colonoscopy study results unfold.Hold firm and buy at current pps. Mr larger order is in at 3.25?

Operational Update: Add’l Colorectal Data Expected Q3, Larger Pancreatic Study, CE Marking…

The Q1 call provided some great insight into where the company is with the various studies and status on when they think they could have an initial commercializable product. The development programs continue to heat up with new studies coming onboard, positive data from ongoing studies either recently announced and/or expected to announce in the very near-term and VNRX seemingly close to filing for CE Mark on an initial assay and having a panel finalized, cleared and on the market – still slated for sometime next year. We continue to think, as we noted in our recent updates, that additional positive clinical data (which could come on a regular basis) has the potential to drive significantly more value.

Thanks rod!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VNRX News